Breaking through the HIV vaccine 'logjam'

February 19, 2018 by Nicholas Ibarra, Santa Cruz Sentinel
Credit: CC0 Public Domain

When biomolecular engineer Phil Berman began his postgraduate work in the 1980s, he had no idea he would spend the rest of his career searching for a way to stop a deadly virus that was then almost entirely known. But around him, as if from nowhere, hundreds of people began to die. He has spent the past three decades looking for an effective vaccine against the AIDS epidemic that would claim more than 20,000 lives in the coastal metropolis alone.

"It was a plague," Berman said during a recent visit to his lab at the University of California, Santa Cruz. "People were dying left and right."

Berman and his team have been searching for a way to make HIV vaccine production faster and more affordable—and, he said, they've found it.

"There are dozens of good ideas for vaccines that are sitting on the shelf because there has been no way to produce them quickly and economically," he said. "We think the technology we developed will break that logjam and allow those brilliant ideas that have been mothballed, basically, because there hasn't been a way to produce them."

The new production method takes advantage of technologies to reduce the time, improve the yield and lower the cost of . A process that used to take two years now takes about two months, while simultaneously producing yields 100 or even 200 times higher.

A potential vaccine needs specific proteins to trigger an immune system response, Berman said. The proteins are produced by derived from the ovaries of Chinese hamsters, with many thousands of potential cell lines needing screening to find those that with a high enough yield.

Screening the cell lines manually in the lab used to take months, Berman said, but the team spent most of the past two years customizing a colony-selection robot to do the job in a matter of days.

The team is able to use those protein-rich cell lines to produce the vaccine in vats much smaller than the beer-vat-size fermenters they would otherwise need. The advance means that the type of large-scale manufacturing facility that would have cost $500 million when Berman first began working on the problem could now be made for about $25 million.

"You can make the drug much cheaper, and much more affordable by the people that need it," Berman said. "It's huge. It's a huge improvement."

Along the way, Berman and graduate student Gabriel Byrne used the gene-editing technology CRISPR to create a cell line that mimics proteins found on the HIV virus, improving the potential protection of the only HIV vaccine to succeed in a human trial.

These days, because of advancements in a regimen of treatments in the 1990s, infection with HIV for most people with access to health care does not mean death, but perpetual treatment. About 1.8 million people a year are infected with HIV, according to statistics compiled by the United Nations.

Berman and a number of researchers worldwide have continued to search for an effective way to immunize the next generation and halt the virus' spread. Berman himself has chased the project from its early days at Genentech in the late 1980s to its spinoff VaxGen, and, finally, to his lab at UCSC's Baskin School of Engineering. At VaxGen, he oversaw an early HIV vaccine trial that failed.

The UCSC lab is ready to begin producing two HIV vaccines on a large scale, Berman said. Their improved version of AIDSVAX—the only to go through clinical trials and demonstrate protective effects—is one, with a second candidate coming from a strain of the virus more commonly found in Southern Africa and India that accounts for a majority of new infections.

Explore further: Scientists report big improvements in HIV vaccine production

10 shares

Related Stories

Scientists report big improvements in HIV vaccine production

February 5, 2018
Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials. One reason for this is the technical ...

Persistence yields progress in AIDS vaccine research

May 14, 2015
Phil Berman has been working to develop an AIDS vaccine for nearly 30 years, first at the pioneering biotech company Genentech, then as cofounder of VaxGen, and now at UC Santa Cruz, where he is the Baskin Professor of Biomolecular ...

Strategy introduces stable components of flu virus for long-lasting, DNA-enhanced protection

January 5, 2018
Getting a flu shot every year can be a pain. One UW Medicine researcher is hoping to make the yearly poke a thing of the past with the development of a universal vaccine that would protect from all strains of influenza virus, ...

Will this year's flu shot be as weak as last season's?

November 8, 2017
(HealthDay)—Lots of people came down with influenza last year despite getting a flu shot—and researchers can't promise this season's vaccine will be any more effective.

New, more effective strategy for producing flu vaccines

December 5, 2016
A team of researchers led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin-Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines ...

Recommended for you

Roadmap reveals shortcut to recreate key HIV antibody for vaccines

December 11, 2018
HIV evades the body's immune defenses through a multitude of mutations, and antibodies produced by the host's immune system to fight HIV also follow convoluted evolutionary pathways that have been challenging to track.

Eliminating the latent reservoir of HIV

December 7, 2018
A new study suggests that a genetic switch that causes latent HIV inside cells to begin to replicate can be manipulated to completely eradicate the virus from the human body. Cells harboring latent HIV are "invisible" to ...

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

Scientists unveil promising new HIV vaccine strategy

November 26, 2018
A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.